R Squared’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

R Squared’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,450	Closed	-$205K	–	1609
2024 Q4	$205K	Buy	+2,450	New	+$201K	0.2%	105

Other funds holding ITCI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

R Squared's ITCI Position: Q1 2025 in Review

R Squared sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 2,450 shares — an estimated $205K sold.

R Squared first reported a position in ITCI in Q4 2024 and held it in 1 quarter. The position peaked at $205K in Q4 2024. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

R Squared reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
R Squared sold 2,450 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $205K.
R Squared first reported a position in Intra-Cellular Therapies Inc. in Q4 2024 and held it in 1 quarter.
R Squared's Intra-Cellular Therapies Inc. position peaked at $205K in Q4 2024.
395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.